Orchestra BioMed Holdings logo

Orchestra BioMed HoldingsNASDAQ: OBIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 August 2020

Next earnings report:

27 March 2025

Last dividends:

N/A

Next dividends:

N/A
$195.55 M
-72%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
77%vs. sector
-59%vs. 3y high
93%vs. sector

Price

after hours | Tue, 19 Nov 2024 21:20:00 GMT
$5.17-$0.66(-11.32%)

Dividend

No data over the past 3 years
$987.00 K$941.50 K
$987.00 K-$15.43 M

Analysts recommendations

Institutional Ownership

OBIO Latest News

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates
zacks.com12 November 2024 Sentiment: POSITIVE

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.38 per share a year ago.

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
globenewswire.com12 November 2024 Sentiment: POSITIVE

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update.

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
zacks.com12 August 2024 Sentiment: NEGATIVE

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.35 per share a year ago.

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
globenewswire.com12 August 2024 Sentiment: POSITIVE

NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.

Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know
zacks.com26 July 2024 Sentiment: POSITIVE

Orchestra BioMed Holdings, Inc. (OBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
zacks.com24 June 2024 Sentiment: POSITIVE

Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
zacks.com03 June 2024 Sentiment: POSITIVE

Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?
zacks.com03 June 2024 Sentiment: POSITIVE

The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research13 May 2024 Sentiment: NEGATIVE

Orchestra BioMed Holdings, Inc. (OBIO) reported a quarterly loss of $0.38 per share, slightly better than the expected loss of $0.40 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.40 per share reported in the same quarter last year.

Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season
Zacks Investment Research16 February 2024 Sentiment: POSITIVE

Orchestra BioMed (OBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What type of business is Orchestra BioMed Holdings?

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

What sector is Orchestra BioMed Holdings in?

Orchestra BioMed Holdings is in the Healthcare sector

What industry is Orchestra BioMed Holdings in?

Orchestra BioMed Holdings is in the Biotechnology industry

What country is Orchestra BioMed Holdings from?

Orchestra BioMed Holdings is headquartered in United States

When did Orchestra BioMed Holdings go public?

Orchestra BioMed Holdings initial public offering (IPO) was on 04 August 2020

What is Orchestra BioMed Holdings website?

https://orchestrabiomed.com

Is Orchestra BioMed Holdings in the S&P 500?

No, Orchestra BioMed Holdings is not included in the S&P 500 index

Is Orchestra BioMed Holdings in the NASDAQ 100?

No, Orchestra BioMed Holdings is not included in the NASDAQ 100 index

Is Orchestra BioMed Holdings in the Dow Jones?

No, Orchestra BioMed Holdings is not included in the Dow Jones index

When was Orchestra BioMed Holdings the previous earnings report?

No data

When does Orchestra BioMed Holdings earnings report?

The next expected earnings date for Orchestra BioMed Holdings is 27 March 2025